Browsing Tag
KRAS mutation
2 posts
Verastem Oncology’s avutometinib plus defactinib trial in LGSOC published in JCO with robust clinical responses
Verastem Oncology published pivotal Phase 2 RAMP 201 trial results in JCO, showing strong response rates for avutometinib plus defactinib in recurrent LGSOC.
Silexion Therapeutics’ SIL-204 shows promise in transforming pancreatic cancer treatment
Silexion Therapeutics, a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies, has released compelling preclinical data for its…